About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Voluntary Withdrawal from OTCQX

December 3, 2018

Click here to read more

Post navigation

Receipt of R&D Tax Incentive

Phosphagenics and Mylan Agree Settlement

Related Posts

CEO Quarterly Update

March 1, 2017

Terumo Shifts Focus from Oxymorphone Patch to Injectables

March 20, 2018

Animal Health Update

May 31, 2021May 31, 2021

Recent Posts

Avecho receives US$3M upfront payment from Sandoz AG
March 28, 2025
MEDIA | Ausbiz
March 7, 2025
MEDIA | Stockhead
March 7, 2025

Categories

Analyst Coverage
Company Announcement
Company Report
Investor Webinar
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.